<DOC>
	<DOCNO>NCT00477412</DOCNO>
	<brief_summary>The goal clinical research study learn bortezomib ( combination rituximab plus 2 different intensive chemotherapy regimen ) help control disease patient mantle cell lymphoma . The safety drug combination also study .</brief_summary>
	<brief_title>Bortezomib ( Velcade ) Plus Rituximab-HyperCVAD Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>You receive 2 different drug combination study . The first combination consist bortezomib rituximab give together intensive chemotherapy regimen ( cyclophosphamide , mesna , doxorubicin , vincristine , dexamethasone ) . The second combination consist bortezomib rituximab give together another intensive chemotherapy regimen ( methotrexate Ara-C [ cytarabine ] ) . If find eligible take part study , first combination give Cycles 1 , 3 , 5 , , need , Cycle 7 . The first combination give outpatient basis ( overnight hospital stay require ) , doctor allows . The second combination give Cycles 2 , 4 , 6 , , need , Cycle 8 . It recommend second combination give inpatient basis study staff monitor effect study drug , safety . You central venous catheter ( CVC ) place chemotherapy give easily . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . First combination : For first combination ( cycle ) , receive rituximab vein 6 hour Day 1 . Cyclophosphamide give vein ( 3 hour time ) twice day Days 2-4 . Mesna give continuously vein Days 2-4 . Doxorubicin give 15-30 minute Day 5 . Vincristine give vein 15-30 minute Days 5 12 . Dexamethasone give mouth vein Days 2-5 Days 12-15 . Bortezomib give second first dose cyclophosphamide immediately vincristine doxorubicin give Day 5 . Other drug give , , chemotherapy help prevent decrease side effect , nausea vomiting . These drug include Zofran® ( ondansetron hydrochloride ) give vein 15-30 minute . Ciprofloxacin hydrochloride give mouth twice day 10 day , Valtrex ( valacyclovir ) give mouth 10 day , fluconazole give mouth every day 10 day . Ciprofloxacin hydrochloride , valacyclovir , fluconazole give day . This first combination alternate every 21 day second combination bortezomib rituximab plus intensive chemotherapy regimen . To help prevent infection , receive Filgrastim ( G-CSF ) injection skin , start 24-36 hour end doxorubicin infusion , day white blood cell recover . Second combination : For second combination ( cycle ) , receive rituximab vein 6 hour Day 1 . Methotrexate give vein 24 hour Day 2 . Cytarabine give vein ( 2 hour time ) every 12 hour Days 3-4 . Other drug give , , chemotherapy help prevent decrease side effect , nausea vomiting . These drug include Zofran® ( ondansetron hydrochloride ) give vein 15-30 minute . Ciprofloxacin hydrochloride give mouth twice day 10 day , Valtrex ( valacyclovir ) give mouth 10 day , fluconazole give mouth daily 10 day . Ciprofloxacin hydrochloride , valacyclovir , fluconazole give day . When receive methotrexate , also give leucovorin mouth help prevent side effect . Blood ( 1 tablespoon ) draw 24 48 hour end methotrexate infusion study doctor learn best stop give leucovorin . To help prevent infection , receive Filgrastim ( G-CSF ) injection skin , start 24-36 hour end doxorubicin infusion , day white blood cell recover . During study , blood ( 1 tablespoon ) draw 2-3 time week routine test . After every 2 cycle , tumor ( ) measure use x-rays CT scan . You bone marrow biopsy/aspirate sample collect . If study doctor think necessary , may MUGA scan ECHO . You exam colon ( colonoscopy ) . The colonoscopy perform receive Cycle 3 combination bortezomib intensive chemotherapy , ( necessary ) Cycle 7 combination bortezomib intensive chemotherapy . Biopsy sample colon take exam . To perform colonoscopy , give laxative day right procedure . You give sedative ( calm ) vein follow insertion long tube rectum right side colon . You remove study disease get bad intolerable side effect occur . After receive study drug , follow-up visit different time point . These visit occur every 3 month 1 year , every 4 month 2 year , every 6 month next 2 year , year indefinitely . During follow-up visit , complete physical exam , blood ( 1 tablespoon ) drawn routine test . You chest x-ray , CT scan , bone marrow aspirate sample collect . This investigational study . All drug use study FDA approve commercially available . Up 110 patient take part study . Up 110 enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Confirmed diagnosis previously untreated nodular diffuse mantle cell lymphoma blastoid cytologic variant . 2 . ECOG Performance status 0 , 1 , 2 . 3 . Serum bilirubin &lt; 1.5mg/dl serum creatinine &lt; 2.0 mg/dl within 14 dyas enrollment ( unless high level due lymphoma ) 4 . Platelet count &gt; 100,000/mm^3 absolute neutrophil count ( ANC ) &gt; 1,000/mm^3 within 14 day enrollment ( unless due lymphoma ) . 5 . Cardiac ejection fraction &gt; /= 50 % ECHO MUGA . 6 . Age 18 year 79 year . 7 . Patients must willing receive transfusion blood product . 8 . Voluntary write IRBapproved informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 9 . Female subject either postmenopausal least 1 year Screening visit surgically sterilize childbearing potential , agree practice 2 effective method birth control , time ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) time sign informed consent 30 day last dose study treatment , agree completely abstain heterosexual intercourse . 10 . Male subject , even surgically sterilize ( ie , status post vasectomy ) agree practice effective barrier contraception entire study treatment period 30 day last dose study treatment , agree completely abstain heterosexual intercourse . 1 . HIV infection . 2 . CNS involvement . 3 . Comorbid medical psychiatric illness preclude treatment intense dose chemotherapy . 4 . Concurrent previous malignancy &lt; 90 % probability survival 5 year . 5 . Patient &gt; /= Grade 2 peripheral neuropathy within 14 day enrollment . 6 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . 7 . Patient hypersensitivity bortezomib , boron mannitol . 8 . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum Bhuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . 9 . Participating clinical trial investigational agent include trial within 14 day start trial throughout duration trial . 10 . Radiation therapy within 3 week randomization . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
	<keyword>Velcade</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Neosar</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Mesna</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>